About: Robatumumab

An Entity of Type: monoclonal antibody, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org:8891

Robatumumab (proposed INN; also known as SCH 717454 and MK-7454) is a monoclonal antibody and an antineoplastic by Merck and Schering-Plough. It binds to CD221, the insulin-like growth factor 1 receptor. Phase 2 clinical trials in patients with colorectal cancer, osteosarcoma and Ewing's sarcoma are complete. Merck has since discontinued development.

Property	Value
dbo:abstract	Robatumumab (proposed INN; also known as SCH 717454 and MK-7454) is a monoclonal antibody and an antineoplastic by Merck and Schering-Plough. It binds to CD221, the insulin-like growth factor 1 receptor. Phase 2 clinical trials in patients with colorectal cancer, osteosarcoma and Ewing's sarcoma are complete. Merck has since discontinued development. (en)
dbo:casNumber	934235-44-6
dbo:fdaUniiCode	V983921H3B
dbo:kegg	D10056
dbo:wikiPageID	21197994 (xsd:integer)
dbo:wikiPageLength	3255 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1001883776 (xsd:integer)
dbo:wikiPageWikiLink	dbr:Schering-Plough dbr:Monoclonal_antibody dbc:Experimental_cancer_drugs dbr:Antineoplastic dbr:International_Nonproprietary_Name dbc:Monoclonal_antibodies dbr:Merck_&_Co. dbr:CD221
dbp:atcPrefix	none (en)
dbp:c	6418 (xsd:integer)
dbp:casNumber	934235 (xsd:integer)
dbp:chemspiderid	none (en)
dbp:h	9960 (xsd:integer)
dbp:kegg	D10056 (en)
dbp:mabType	mab (en)
dbp:n	1732 (xsd:integer)
dbp:o	1992 (xsd:integer)
dbp:s	42 (xsd:integer)
dbp:source	u (en)
dbp:target	dbr:CD221
dbp:type	mab (en)
dbp:unii	V983921H3B (en)
dbp:verifiedfields	changed (en)
dbp:verifiedrevid	464383074 (xsd:integer)
dbp:watchedfields	changed (en)
dbp:wikiPageUsesTemplate	dbt:Antineoplastic-drug-stub dbt:Drugbox dbt:Reflist dbt:Short_description dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Keggcite dbt:Growth_factor_receptor_modulators dbt:Monoclonal-antibody-stub dbt:Monoclonals_for_tumors
dcterms:subject	dbc:Experimental_cancer_drugs dbc:Monoclonal_antibodies
gold:hypernym	dbr:Antibody
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody yago:WikicatMonoclonalAntibodies yago:Abstraction100002137 yago:Antibody115027189 yago:Chemical114806838 yago:Compound114818238 yago:Macromolecule114944888 yago:Material114580897 yago:Matter100020827 yago:Molecule114682133 yago:MonoclonalAntibody115029781 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Protein114728724 yago:Relation100031921 dbo:Drug yago:Substance100019613 yago:Thing100002452 yago:Unit109465459
rdfs:comment	Robatumumab (proposed INN; also known as SCH 717454 and MK-7454) is a monoclonal antibody and an antineoplastic by Merck and Schering-Plough. It binds to CD221, the insulin-like growth factor 1 receptor. Phase 2 clinical trials in patients with colorectal cancer, osteosarcoma and Ewing's sarcoma are complete. Merck has since discontinued development. (en)
rdfs:label	Robatumumab (en)
owl:sameAs	freebase:Robatumumab yago-res:Robatumumab wikidata:Robatumumab dbpedia-fa:Robatumumab https://global.dbpedia.org/id/4uFV3 dbr:Robatumumab
prov:wasDerivedFrom	wikipedia-en:Robatumumab?oldid=1001883776&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:Robatumumab
is dbo:wikiPageWikiLink of	dbr:List_of_therapeutic_monoclonal_antibodies dbr:List_of_drugs:_Rf–Rz
is foaf:primaryTopic of	wikipedia-en:Robatumumab